Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial

• Main Authors: Takaichi Suehiro (Author), Kazuhiko Tsuruya (Author), Hisako Yoshida (Author), Hiroaki Tsujikawa (Author), Shunsuke Yamada (Author), Shigeru Tanaka (Author), Akihiro Tsuchimoto (Author), Masahiro Eriguchi (Author), Kiichiro Fujisaki (Author), Kumiko Torisu (Author), Toshiaki Nakano (Author), Takanari Kitazono (Author)
• Format: Book
• Published: Karger Publishers, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Angiotensin receptor blockers (ARBs) are preferably used in hypertensive patients with CKD. Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood. We compared the antiproteinuric effect of azilsartan and candesartan in CKD patients in an o...